Stimulated by the pro-inflammatory cytokines TNF-α or IFN-γ or both, the expression of EBI3 and p35 increased and this effect was attenuated by pretreatment with peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone, suggesting a potential role of IL-35 in the progression of atherosclerosis. The gene discussed is PPARG; the disease is atherosclerosis.